Treventis VP Research Dr. Marcia Taylor was an invited speaker at the Targeting Protein Misfolding Summit, held virtually from March 15-17, 2021. Dr. Taylor presented a talk about our small molecule lead program in tauopathy and Alzheimer’s entitled “Use of in vitro and in vivo models to measure reduction of tau and amyloid beta oligomer.” […]
Dr. Marcia Taylor was in attendance at the virtual AD/PD conference taking that took place on March 9-14, 2021. This event specializes in Alzheimer’s and Parkinson’s research and is ordinarily held in Europe each spring. Dr. Taylor noted that presented work demonstrated impressive advances in the field of plasma biomarkers for diagnosing and following course […]
Treventis scientists Drs. Christopher Barden and Ross Mancini and SAB member Dr. Janice Robertson attended the 31st Virtual International Symposium on ALS/MND that was held virtually on December 9-11th, 2020. Dr. Robertson’s Ph.D. student Marc Shenouda presented ‘Identification and validation of small molecules targeting the amyloidogenic core of TDP-43 as therapeutics for ALS/FTLD’ on identifying […]
Treventis was well represented at the Alzheimer Association International Conference, running from Jul 27-31, 2020 (originally scheduled for Amsterdam, the Netherlands, and converted to virtual format due to COVID-19). CEO Christopher Barden, VP Research Marcia Taylor, CSO Mark Reed, and Chief Medical Officer Dr. Donald Weaver were delegates at the conference, the preeminent global annual […]
LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to perform a repurposing clinical trial in inhaled furosemide for patients on mechanical ventilation due to COVID-19. This funding, awarded through a highly competitive rapid-response process starting on March 30, was awarded on Jun 30. This […]
Not to be deterred by COVID-19, Treventis attended the BIO Digital International Convention (formerly scheduled for San Diego, California; instead held digitally) with more than 7,000 attendees and 64 countries represented. This conference hosts delegates passionate about creating new opportunities to partner and collaborate on innovative drug projects aimed at improving the lives of patients. […]
Treventis CSO Mark Reed was in attendance at the 8th Neurodegenerative Drug Development Summit (previously known as World CNS) held in Boston, Massachusetts from Feb 25-27. Among the speakers were Dementia Discovery Fund (and past Treventis advisor) Barbara Tate. This year’s main topics were progress in biomarker technologies and gene therapy, as well as emergence […]
Treventis VP Research Marcia Taylor has attended Tau2020 in Washington, DC, which is one of the world’s biggest conferences focusing on tau: the hallmark of many neurodegenerative diseases including Alzheimer’s disease. This conference covers not only on expanding the public’s awareness of the current tau research but also creating forward movement for it by engaging […]
Treventis founders Dr. Donald Weaver, Mark Reed, and Christopher Barden have supervised research at Toronto hospital UHN into new methods for predicting blood-brain permeability. This research has culminated in two recent papers. Two papers by primary author and UHN postdoctoral associate Mayuri Gupta discuss the Blood-Brain Barrier (BBB) and the Brain Exposure Efficiency (BEE) scoring […]
Treventis CEO Christopher Barden attended BioPort, Atlantic Canada’s largest health and life sciences event in Halifax, Nova Scotia. BioPort is the region’s annual forum for education, information, and inspiration of the Atlantic Canadian life sciences ecosystem. At the event, Dr. Barden networked with the local community about Treventis and particularly as regards its Halifax-based butyrylcholinesterase […]